Immune thrombocytopenia among patients with cancer and its response to treatment

Yousef, Mahmoud H Ayesh Haj; Alawneh, Khaldoon; Zahran, Deeb Jamil; Aldaoud, Najla; Khader, Yousef

doi:10.1111/ejh.13091

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of lymphomas connected to an autoimmune disorder is estimated to be between 7% [e.g., Hodgkin's lymphoma (HL)] and 18% (e.g., marginal zone lymphoma) ( 28 ). Inversely, ITP occurs in the context of malignant lymphoproliferation ( 29 ), such as chronic lymphocytic leukemia ( 30 ), HL ( 31 ), and various types of non-Hodgkin's lymphomas (NHLs) ( 32 , 33 ); it is rarely associated with T-cell NHL ( 29 ). The prevalence of ITP in HL has been estimated at 0.2–1% ( 31 , 34 ), NHL at 0.76% ( 32 ), and chronic lymphocytic leukemia (CLL) at 1–5% ( 30 ).…”

Section: Cancer and Autoimmunity (Gray Box)mentioning

confidence: 99%

Understanding Immune Thrombocytopenia: Looking Out of the Box

et al. 2021

View full text Add to dashboard Cite

The pathogenesis of immune thrombocytopenia (ITP) is increasingly being elucidated, and its etiology is becoming more frequently identified, leading to a diagnostic shift from primary to secondary ITP. The overlap between autoimmunity, immunodeficiency, and cancer is evident, implying more interdisciplinarity in daily care. This mini-review is based on an expert meeting on ITP organized by the Intercontinental Cooperative ITP Study Group and presents the challenges of hematologists in understanding and investigating “out of the box” concepts associated with ITP.

show abstract

Section: Cancer and Autoimmunity (Gray Box)mentioning

confidence: 99%

Understanding Immune Thrombocytopenia: Looking Out of the Box

et al. 2021

View full text Add to dashboard Cite

show abstract

Navigating the Landscape of Cancer-Induced Thrombocytopenia: Current Challenges and Emerging Advances

Sharma,

Raut,

Dhikale

et al. 2024

Industrial Microbiology and Biotechnology

View full text Add to dashboard Cite

Acquired haemophilia in patients with malignant disease: A case report

Krašek

Kotnik

Zavrtanik

et al. 2021

WJCC

View full text Add to dashboard Cite

BACKGROUND Acquired haemophilia is a rare coagulation disorder characterized by autoantibodies against coagulation factor VIII leading to severe and potentially life-threatening haemorrhages. The underlying disorder causing the development of an autoimmune phenomenon is not always known, but 10%-15% could be linked to malignancies. Patients with cancer who require surgical resection represent a treatment challenge not solely due to increased risk of bleeding but also due to adverse events of immunosuppressive therapy. CASE SUMMARY We present the case of a 67-year-old man with non-metastatic adenocarcinoma of the distal bile duct who developed concomitant acquired haemophilia a month after having been diagnosed with malignant disease. Haemostasis was established with recombinant activated factor VII, and immunosuppressive therapy was started immediately. An extensive surgical procedure was performed in order to remove the cancer and, therefore, eliminate the inhibitory autoantibodies. Due to a complicated postoperative course, relatively short period of treatment and likelihood of micrometastases, no improvement in the patient’s status was observed. Diagnosis and treatment of acquired haemophilia as well as other coagulation disorders in patients with cancer are discussed. CONCLUSION Prompt diagnosis of acquired haemophilia is required in order to start appropriate treatment and reduce mortality. Among patients with cancer, other causes of abnormal bleeding related to malignancy should be considered.

show abstract

Immune thrombocytopenia among patients with cancer and its response to treatment

Abstract: Patients with lymphomas had higher rates of ITP than did patients with solid cancers. Treatment of ITP-associated cancer may improve the platelets count.

Cited by 3 publications

References 40 publications

Understanding Immune Thrombocytopenia: Looking Out of the Box

Understanding Immune Thrombocytopenia: Looking Out of the Box

Navigating the Landscape of Cancer-Induced Thrombocytopenia: Current Challenges and Emerging Advances

Acquired haemophilia in patients with malignant disease: A case report

Contact Info

Product

Resources

About